Form 4: Whitehawk Therapeutics Executive Bryan Ball Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Bryan Ball, Chief Technical Operations Officer and SVP of Manufacturing Operations at Whitehawk Therapeutics, acquired stock options and restricted stock units on April 1, 2025.
Summary
- Bryan Ball, an executive at Whitehawk Therapeutics, acquired stock options and restricted stock units on April 1, 2025.
- He obtained options to purchase 366,532 shares of common stock at an exercise price of $1.70 per share.
- These options vest over four years, starting April 1, 2025, with 25% vesting after one year and the remainder vesting monthly thereafter.
- Ball also received 366,532 restricted stock units (RSUs), each representing a contingent right to receive one share of Whitehawk Therapeutics common stock.
- These RSUs vest entirely on April 1, 2026, contingent upon continued service.
- The reported transactions were signed off by Stephen Rodin, as Attorney-in-Fact, on April 3, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The vesting schedule suggests a long-term commitment, which is mildly positive.
Positives
- The granting of stock options and RSUs to a key executive like Bryan Ball can be seen as a positive sign, aligning his interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the executive.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The granting of stock options and RSUs is a common method of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option and RSU grants are common compensation tools in the biotech industry.
- Vesting schedules, such as the four-year vesting for the options and one-year vesting for the RSUs, are typical.
- Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- Shareholders may view the granting of stock options and RSUs as a way to incentivize management and align their interests with the company's long-term success.
- Employees may see this as a positive sign, indicating the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of earliest transaction: Grant date of stock options and restricted stock units. |
| 04/01/2025 | Vesting Commencement Date for both stock options and restricted stock units. |
| 04/01/2026 | Date when 100% of the restricted stock units vest. |
| 04/01/2035 | Expiration date of the stock options. |
| 04/03/2025 | Date of the Form 4 filing. |
Keywords
Whitehawk Therapeutics, Bryan Ball, stock options, restricted stock units, RSU, Form 4, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.